Long‐interval T2‐weighted subtraction magnetic resonance imaging: A powerful new outcome measure in multiple sclerosis trials

Bastiaan Moraal, I.j. van den Elskamp, Dirk L. Knol, Bernard M.j. Uitdehaag, Jeroen J.g. Geurts, Hugo Vrenken, Petra J. W. Pouwels, Ronald A. van Schijndel, Dominik Meier, Charles R.g. Guttmann, Frederik BarkhofAnnals 2009 · DOI

Abstract

Compared with monthly Gd-T1w imaging, long-interval T2w-Sub MRI exhibited increased power to assess treatment efficacy, and could greatly increase the cost-effectiveness of phase 2 MS trials by limiting the number of patients, contrast injections, and MRI scans needed.
BibTeX
@article{moraal2009longinterval,
  author = {Bastiaan Moraal and I.J. van den Elskamp and Dirk L. Knol and Bernard M.J. Uitdehaag and Jeroen J.G. Geurts and Hugo Vrenken and Petra J. W. Pouwels and Ronald A. van Schijndel and Dominik Meier and Charles R.G. Guttmann and Frederik Barkhof},
  title = {{Long‐interval T2‐weighted subtraction magnetic resonance imaging: A powerful new outcome measure in multiple sclerosis trials}},
  journal = {Annals},
  year = {2009},
  doi = {10.1002/ana.21958},
}

Loading related content...

Figure